Introduction
The role of oncogene activation by amplification in the generation and progression of most human malignancies is poorly defined. myc family (c-myc, N-myc, and L-myc) DNA amplification has been described in a variety of cancer cell lines and tumor specimens. This includes c-myc DNA amplification, which has been previously reported in tumor cell lines established from patients with leukemia (1), colon cancer (2) , breast cancer (3) , gastric cancer (4) , glioblastoma (5) , non-small cell lung cancer (6) , and small cell lung cancer (6, 7) . N-myc, which shares DNA sequence homology with c-myc, is amplified in some tumors and tumor cell lines derived from neuroendocrine tissues, including neuroblastoma and retinoblastoma (8) (9) (10) (11) (12) . N-myc amplification occurs in childhood neuroblastoma in 33% of patients' tumors and is associated with advanced stage disease (10) as well as more rapid tumor progression (11) . Small cell lung cancer cell lines and tumors have also been shown to be amplified for the N-myc oncogene (13) . In addition, L-myc, a new oncogene sharing DNA sequence homology with both c-Receivedfor publication 20 August 1986 and in revisedform 23 January 1987. myc and N-myc, has been found to be amplified and expressed in small cell lung cancer cell lines and tumors (14) . However, the relationship between the clinical status and course ofa cohort of patients and myc family DNA amplification in their tumor cell lines remains to be defined.
In addition, little information is available concerning whether the biology of human tumor cell lines is representative of the broad spectrum of human tumor biology. In childhood neuroblastoma where some data exists, nearly all cell lines are amplified for the oncogene, N-myc (8, 9) , whereas only one third of the actual tumor specimens have DNA amplification of N-myc (10). Neuroblastoma patients whose tumors have DNA amplification of N-myc are more likely to present with advanced-stage disease and have a more rapid tumor progression (10, 1 1) . This suggests that the neuroblastoma cell lines, nearly all of which have Nmyc amplification, may not be typical of the biologic characteristics of all childhood neuroblastomas.
44 patients with small cell lung cancer who were staged and treated on prospective therapeutic clinical trials at the National Cancer Institute-Navy Medical Oncology Branch also had tumor cell lines established (15, 16) . We determined the DNA copy number of c-myc, N-myc, L-myc in these tumor lines and correlated this data with the clinical information and outcome. This large number of small cell lung cancer cell lines with complete clinical information on the patients from whom the cell lines were established allowed an evaluation of the relationship between oncogene amplification and the patients' clinical characteristics and course.
Methods
We treated 227 newly diagnosed patients with histologically confirmed small cell lung cancer from 1977 through July of 1984 in a series of intramural National Cancer Institute (NCI)' therapeutic clinical trials.
Following an evaluation previously described, patients were assigned a Zubrod performance status (17) and designated as having either limitedor extensive-stage disease (18) . All patients were treated with combination chemotherapy with or without chest or cranial irradiation.
The 227 patients underwent diagnostic and therapeutic procedures (bone marrow aspirate and biopsy, thoracentesis, and surgical resection oftumor masses) during staging and treatment from which tumor tissue was obtained. When adequate tumor tissue was available after the diagnostic needs ofpathology were fulfilled, the specimens were processed and used to attempt to establish cell lines as previously described (15, 16) . After 3-6 mo of continued growth in cell culture media, the tumor cells that could grow at a relatively low density free of stromal cell contamination and could be routinely maintained in a variety of media, 227 small cell lung cancer patients All patients from whom these cell lines were established were identified and the clinical course was reviewed. The age, sex, stage ofdisease, Zubrod performance status, sites ofextensive disease, date of initial chemotherapy, number of drugs administered, duration of therapy, date cell lines were started, site from which the cell line was started, and the date of death were noted.
The c-myc, N-myc, and L-myc DNA copy number in the 44 cell lines was determined by harvesting the cells during log phase growth, preparing DNA (19) , digesting the DNA with the Eco RI restriction endonuclease, electrophoresing the DNA on 0.8% agarose gels, and transferring the DNA to nitrocellulose filters by the method of Southern (20). The DNA was hybridized to 32P-labeled purified DNA fragments of c-myc, a Cla I-Eco RI fragment containing the third exon (21); Nmyc, an Eco RI-Bam HI fragment containing the second exon (8) ; and L-myc, a Sma I-Eco RI fiagment 3 to the gene containing the homology region to the second exon of c-mnyc and N-myc (14) . The filters were washed as previously described (6) and were exposed to X-ray film. NCI small cell lung cancer cell lines H146 and H187 were used as controls for a single copy of c-myc, N-myc, and L-myc. The c-myc, N-myc, and L-myc copy number of the amplified cell lines was determined by densitometry relative to the single copy control cell lines. The variations in the amount of DNA loaded per lane were adjusted by standardizing the c-myc, N-myc. and L-myc signal to the signal made from a single copy oxytocin gene, a 10-kb Eco RI fragment (22) . The copy number of the myc genes was considered to be amplified if the densitometry readings were fourfold greater than the single copy gene controls.
The survival time of the patients was calculated from the date of initial chemotherapy; complete follow-up was available on all patients. Contingency tables were analyzed using the Pearson chi-square statistic, adjusted for continuity where appropriate. Continuous data were compared using the Wilcoxon two-sample test. Time-to-failure curves were calculated using the Kaplan-Meier method (23). The entire curves were compared one to another using Gehan's generalized Wilcoxon statistic (24). All cited P values correspond to two-sided tests.
Results
DNA from 13 of the 44 small cell lung cancer cell lines was amplified for one of the myc family oncogenes, 5 for c-myc, 4 for N-myc, and 4 for L-myc (Figs. 1-3) . The rearranged amplified c-myc bands in three cell lines ( Fig. 1; H60 , H82, and H524) have been previously observed and all these cell lines express a normal size 2.3-kb c-myc mRNA (6, 16) . The rearranged amplified N-myc band in H526 (Fig. 2) has been previously reported and a novel-sized 1.8-kb N-myc mRNA is detected in the cell line (13) . Karyotype information was available on 14 of the 44 cell lines studied (25). Homogeneous staining regions (HSR) or double-minute chromosomes (DM) were found in three of the four myc family amplified cell lines studied. The c-mw amplified cell lines H60 and H82 had DMs and an HSR, respectively. The N-myc amplified cell line H69 had DMs. H211, a c-myc amplified cell line, and all 10 other tonamplified cell lines studied did not have either DMs or HSRs.
The incidence of myc family DNA amplification was related to the treatment status of the patient at the time the tumor cell line was established (Table I) . DNA from 19 tumor cell lines established from untreated small cell lung cancer patients was studied. Only two lines ( 1%) had DNA amplification (one Nmyc and one L-myc). 25 small cell lung cancer cell lines were established from patients whose tumor was progressing after an initial regression following the administration ofchemotherapy. DNA from 11 of these 25 cell lines (44%) was amplified for one of the myc family oncogenes (5 for c-myc, 3 for N-myc, and 3 for L-myc). from untreated patients (P = 0.04). In this series of tumor cell lines; c-myc DNA amplification was seen only in cell lines established from treated patients (Table I) .
While analyzing the influence of myc family DNA amplification on patient survival, we noted the survival of small cell lung cancer patients who had cell lines established from their tumors before starting therapy was markedly shorter than nearly all series of small cell lung cancer patients reported (26) (27) (28) (Fig. 4 A) in the 19 patients from whom cell lines were established (P < 0.001). There was no marked difference between these two groups' characteristics with no sta- (Fig. 4 B; (14) . Box below represents the L-myc probe. Four cell lines have DNA amplified for L-myc (H298, H378, H462, and N69 1), which appears at either 10-kb or 6.6-kb because of an Eco RI restriction fragment polymorphism. H462 was established from an untreated small cell lung cancer patient and the other three from treated patients (H298, H378, and N69 1).
stage disease compared with 1 of 19 (5%) of the patients who had tumor cell lines started at the time of diagnosis. Limited stage disease is associated with prolonged survival in small cell lung cancer (26) (27) (28) . In addition, the 25 patients whose tumor cell lines were established at the time oftheir relapse had a more favorable initial response to chemotherapy than the initial response of patients who had tumor cell lines started before the initiation of chemotherapy: 8 complete responses (32%) vs. 1 complete response (5%). A complete response to chemotherapy is also associated with prolonged survival in this tumor (26, 27) .
The survival of the treated small cell lung cancer patients from whom tumor cell lines were established was correlated with the myc family DNA amplification status (Fig. 5, A-C) . Chemotherapy-treated small cell lung cancer patients whose cell lines (Fig. 5, B and C) although the number of patients available for analysis is small.
Discussion
In our series of small cell lung cancer patients, myc family DNA amplification was more common in cell lines established from treated rather than untreated patients. Recently investigators have studied oncogene amplification including c-myc and Nmyc in human cancer and its relationship to the clinical presentation and course of the patients (10,1, 30, 31) . Yokota et al. (30) have identified c-myc DNA amplification in 10 of 80 (13%) human carcinoma and sarcoma fresh tumor specimens. They reported the c-myc DNA amplification was more commonly found in the more aggressive and disseminated primary tumors. In addition, Wong et al. have studied DNA extracted from paraffin-embedded small cell lung cancer specimens and found greater than threefold DNA amplification of c-myc or N-myc in 5 of 41 (12%) tissue specimens. Neither of these groups documented the treatment status of the patients from whom the specimens were obtained. 
